Unknown

Dataset Information

0

Identification of a novel germ-line mutation in the TP53 gene in a Mexican family with Li-Fraumeni syndrome.


ABSTRACT: BACKGROUND: Germ-line mutations of the TP53 gene are known to cause Li-Fraumeni syndrome, an autosomal, dominantly inherited, high-penetrance cancer-predisposition syndrome characterized by the occurrence of a variety of cancers, mainly soft tissue sarcomas, adrenocortical carcinoma, leukemia, breast cancer, and brain tumors. METHODS: Mutation analysis was based on Denaturing high performance liquid chromatography (DHPLC) screening of exons 2-11 of the TP53 gene, sequencing, and cloning of DNA obtained from peripheral blood lymphocytes. RESULTS: We report herein on Li Fraumeni syndrome in a family whose members are carriers of a novel TP53 gene mutation at exon 4. The mutation comprises an insertion/duplication of seven nucleotides affecting codon 110 and generating a new nucleotide sequence and a premature stop codon at position 150. With this mutation, the p53 protein that should be translated lacks the majority of the DNA binding domain. CONCLUSION: To our knowledge, this specific alteration has not been reported previously, but we believe it is the cause of the Li-Fraumeni syndrome in this family.

SUBMITTER: Taja-Chayeb L 

PROVIDER: S-EPMC2806269 | biostudies-literature | 2009

REPOSITORIES: biostudies-literature

altmetric image

Publications

Identification of a novel germ-line mutation in the TP53 gene in a Mexican family with Li-Fraumeni syndrome.

Taja-Chayeb Lucia L   Vidal-Millán Silvia S   Gutiérrez-Hernández Olga O   Trejo-Becerril Catalina C   Pérez-Cárdenas Enrique E   Chávez-Blanco Alma A   de la Cruz-Hernández Erick E   Dueñas-González Alfonso A  

World journal of surgical oncology 20091217


<h4>Background</h4>Germ-line mutations of the TP53 gene are known to cause Li-Fraumeni syndrome, an autosomal, dominantly inherited, high-penetrance cancer-predisposition syndrome characterized by the occurrence of a variety of cancers, mainly soft tissue sarcomas, adrenocortical carcinoma, leukemia, breast cancer, and brain tumors.<h4>Methods</h4>Mutation analysis was based on Denaturing high performance liquid chromatography (DHPLC) screening of exons 2-11 of the TP53 gene, sequencing, and clo  ...[more]

Similar Datasets

| S-EPMC5457344 | biostudies-literature
| S-EPMC4940490 | biostudies-literature
| S-EPMC5378014 | biostudies-literature
| S-EPMC6300601 | biostudies-literature
| S-EPMC5794730 | biostudies-literature
| S-EPMC3135649 | biostudies-literature
| S-EPMC5824314 | biostudies-literature